International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #8: Epidemiology and Risk Factors for Type 1 Diabetes Mellitus Part 2 of 5

References:

1. Mayer-Davis E: Increase in prevalence of type 1 diabetes from the SEARCH for Diabetes in Youth Study: 2001 to 2009, 2012. [Abstract]
2. Lawrence JM: Trends in incidence of type 1 diabetes among non-Hispanic white youth in the US, 2002–2009, 2012. [Abstract]
3. Rewers A, Klingensmith G, Davis C, et al.: Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Journal of Pediatrics 2008;121(5):e1258–e1266.
4. Patterson CC, Gyurus E, Rosenbauer J, et al.: Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012;55(8):2142–2147.
5. Fourlanos S, Varney MD, Tait BD, et al.: The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008;31(8):1546–1549.
6. Liese AD, D'Agostino RB, Jr., Hamman RF, et al.: The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118(4):1510–1518.
7. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: Annals of the N Y Academy of Sciences 2008; 1150:1–13.
8. Harjutsalo V, Sjoberg L, Tuomilehto J: Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371(9626):1777–1782.
9. Haynes A, Bulsara MK, Bower C, et al.: Cyclical variation in the incidence of childhood type 1 diabetes in Western Australia (1985–2010). Diabetes Care 2012; 35(11):2300–2302.
10. Borchers AT, Uibo R, Gershwin ME:The geoepidemiology of type 1 diabetes. Autoimmunity Reviews 2010;9(5):A355–A365.
11. The DiaMond Project Group: Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. Diabetic Medicine 2006;23(8):857–866.
12. GreenA, Patterson CC: Trends in the incidence of childhood-onset diabetes in Europe 1989–1998. Diabetologia 2001;44(Suppl 3): B3–B8.
13. Karvonen M, Viik-Kajander M, Moltchanova E, et al.: Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (Dia-Mond) Project Group. Diabetes Care 2000;23(10):1516–1526.
14. Zhang H, Xia W, Yu Q, et al. Increasing incidence of type 1 diabetes in children aged 0–14 years in Harbin, China (1990–2000). Primary Care Diabetes 2008;2(3):121–126.
15. Dabelea D, Bell RA, D'Agostino RB, Jr,., et al.: Incidence of diabetes in youth in the United States. JAMA 2007;297(24):2716–2724.
16. Kostraba JN, Gay EC, Cai Y, et al.: Incidence of insulin-dependent diabetes mellitus in Colorado. Epidemiology 1992;3:232–238.
17. Gujral JS, McNally PG, Botha JL, Burden AC: Childhood-onset diabetes in the white and South Asian population in Leicestershire, UK. Diabetic Medicine 1994;11(6):570–572.

18. Dahlquist GG, Nystrom L, Patterson CC: Incidence of type 1 diabetes in Sweden among individuals aged 0–34 years, 1983–2007: an analysis of time trends. Diabetes Care 2011;34(8):1754–1759.
19. Bruno G,Merletti F, Biggeri A, et al.: Increasing trend of type I diabetes in children and young adults in the province of Turin (Italy). Analysis of age, period and birth cohort effects from 1984 to 1996. Diabetologia 2001;44(1):22–25.
20. Gale EA, Gillespie KM: Diabetes and gender. Diabetologia 2001; 44(1):3–15.
21. Serban V, Timar R, Dabelea D, et al.: The epidemiology of childhood-onset type 1 diabetes mellitus in Romania. ONROCAD Study Group. National Romanian Organisation for the Care of Diabetic Children and Adolescents. Journal of Pediatric Endocrinology and Metabolism 2001;14(5):535–541.
22. Diabetes Epidemiology Research International Group: Secular trends in incidence of childhood IDDM in 10 countries. Diabetes 1990;39:858–864.
23. EURODIAB ACE Study Group: Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000;355(9207):873–876.
24. Rosenbauer J, Herzig P, von Kries R, et al.: Temporal, seasonal, and geographical incidence patterns of type I diabetes mellitus in children under 5 years of age in Germany. Diabetologia 1999; 42(9):1055–1059.
25. Schoenle EJ, Lang-Muritano M, Gschwend S, et al.: Epidemiology of type I diabetes mellitus in Switzerland: steep rise in incidence in under 5 year old children in the past decade. Diabetologia 2001;44(3):286–289.
26. Verge CF, Gianani R, Kawasaki E, et al.: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45(7):926–933.
27. Williams AJ, Bingley PJ, Bonifacio E, et al.: A novel micro-assay for insulin autoantibodies. Journal of Autoimmunity 1997;10(5): 473–478.
28. Robles DT, Eisenbarth GS,Wang T, et al.: Identification of children with early onset and high incidence of anti-islet autoantibodies. Clinical Immunology 2002;102(3):217–224.
29. Kupila A, Keskinen P, Simell T, et al. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes 2002;51(3):646–651.
30. Orban T, Sosenko JM,Cuthbertson D, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32(12):2269–2274.
31. Siljander HT, Simell S, Hekkala A, et al.: Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 2009;58(12):2835–2842.
32. Redondo MJ, Jeffrey J, Fain PR, et al.: Concordance for islet autoimmunity among monozygotic twins. New England Journal of Medicine 2008;359(26):2849–2850.
33. Harjutsalo V, Reunanen A, Tuomilehto J: Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring. Diabetes 2006; 55(5):1517–1524.
34. Koczwara K, Bonifacio E, Ziegler AG: Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes 2004;53(1):1–4.
35. Rewers M, Bugawan TL, Norris JM, et al.: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996;39:807–812.

36. Deschamps I, Khalil I. The role of DQ alpha-beta heterodimers in genetic susceptibilty to insulin-dependent diabetes. Diabetes/Metabolism Reviews 1993;9:71–92.
37. Valdes AM, Erlich HA, Noble JA: Human leukocyte antigen class I B and C loci contribute to Type 1 Diabetes (T1D) susceptibility and age at T1D onset. Human Immunology 2005;66(3): 301–313.
38. Nejentsev S, Howson JM, Walker NM, et al.: Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450(7171):887–892.
39. Aly TA, Ide A, Jahromi MM, et al.: Extreme genetic risk for type 1A diabetes. PNAS 2006;103(38):14074–14079.
40. Baschal EE, Aly TA, Babu SR, et al.: HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes 2007;56(9):2405–2409.
41. Steck AK, Armstrong TK, Babu SR, Eisenbarth GS: Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. Diabetes 2011;60(3):1045–1049.
42. Erlich H, Valdes AM, Noble J, et al.: HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008;57(4):1084–1092.
43. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447(7145): 661–678.
44. Steck AK,Wong R,Wagner B, et al.: Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR,DQ genotypes. Diabetes 2012;61(3):753–758.
45. Vang T, Congia M, Macis MD, et al.: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nature Genetics 2005;37(12):1317–1319.
46. Rieck M, Arechiga A, Onengut-Gumuscu S, et al.: Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. Journal of Immunology 2007;179(7):4704–4710.
47. Yu L, Cuthbertson DD, Maclaren N, et al.: Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 2001;50(8):1735–1740.
48. Wenzlau JM, Moua O, Sarkar SA, et al.: SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Annals of the N Y Academy of Sciences 2008; 1150:256–259.
49. Achenbach P, Schlosser M, Williams AJ, et al.: Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clinical Immunology 2007;122(1):85–90.
50. Torn C, Mueller PW, Schlosser M, et al.: Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51(5):846–852.
51. Achenbach P, Bonifacio E,Williams AJ, et al.: Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia 2008;51(3):488–492.
52. Steck AK, Johnson K, Barriga KJ, et al.: Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1

diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care 2011; 34(6):1397–1399.
53. Bingley PJ, Gale EA: Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49(5):881–890.
54. Ekoé J-M, Rewers M,Williams R, Zimmet P (eds.): The Epidemiology of Diabetes Mellitus Textbook. JohnWiley & Sons, Ltd., 2008.
55. Ziegler A-G, Hillebrand B, Rabl W, et al.: On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 1993;36:402–408.
56. Barker JM, Barriga KJ, Yu L, et al.: Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Journal of Clinical Endocrinology & Metabolism 2004;89(8):3896–3902.
57. Kimpimaki T, Knip M: Disease-associated autoantibodies as predictive markers of type 1 diabetes mellitus in siblings of affected children. Journal of Pediatric Endocrinology and Metabolism 2001;14(Suppl 1):575–587.
58. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatric Diabetes 2007;8(5): 286–298.
59. Siljander HT, Veijola R, Reunanen A, et al.: Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007;50(11):2272–2275.
60. Achenbach P, Koczwara K, Knopff A, et al.: Mature high-affinity immune responses to (pro) insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Journal of Clinical Investigation 2004;114(4):589–97.
61. Laakso M, Pyorala K: Age at onset and type of diabetes. Diabetes Care 1985;8:114–117.
62. Fuchtenbusch M, Ferber K, Standl E, Ziegler AG: Prediction of type 1 diabetes postpartumin patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 1997;46(9):1459–1467.
63. Turner R, Stratton I,Horton V, et al.: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350(9087):1288–1293.
64. Chase HP, Dolan LM, Krischer JP, et al.: First phase insulin release (FPIR) during the intravenous glucose tolerance test (IV-GTT) as a risk factor for type 1 diabetes. Journal of Pediatrics 2001; 138(2):244–249.
65. Keskinen P, Korhonen S, Kupila A, et al.: First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia 2002;45(12):1639–1648.
66. Eisenbarth GS, Verge CF, Allen H, Rewers MJ: The design of trials for prevention of IDDM. Diabetes 1993;42(7):941–947.
67. Keymeulen B, Walter M, Mathieu C, et al.: Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53(4):614–623.
68. Sosenko JM, Palmer JP, Greenbaum CJ, et al.: Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes PreventionTrial -Type 1. Diabetes Care 2007;30(1):38–42.

69. Sosenko JM, Krischer JP, Palmer JP, et al.: A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31(3): 528–533.
70. Leech NJ, Rowe RE, Bucksa J, McCulloch DK: HbA1c may be an early indicator of islet cell dysfunction. Autoimmunity 1993;15(Suppl):75. [Abstract]
71. Stene LC, Barriga K, Hoffman M, et al.: Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatric Diabetes 2006;7(5):247–253.
72. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32(7):1327–1334.
73. Vehik K,Cuthbertson D, Boulware D, et al.: Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care 2012; 35(9):1821–1825.
74. The Diabetes Control and Complications Trial Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual B-cell function: observations during eligibility testing for the diabetes control and complications trial. Journal of Clinical Endocrinology & Metabolism 1987;65:30–36.
75. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Annals of Internal Medicine 1998;128(7):517–523.
76. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al.: Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31(11):2188–2192.
77. Greenbaum CJ, Beam CA, Boulware D, et al.: Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61(8):2066–2073.
78. Kaprio J, Tuomilehto J, Koskenvuo M, et al.: Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992;35(11):1060–1067.
79. Conrad B, Weidmann E, Trucco G, et al.: Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 1994;371(6495):351–355.
80. Honeyman MC, Coulson BS, Stone NL, et al.: Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000;49(8):1319–1324.
81. Coppieters KT, Boettler T, von Herrat M: Virus infections in type 1 diabetes. Cold Spring Harbor Perspectives in Medicine 2012; 2(1):a007682.
82. Stene LC, Oikarinen S, Hyoty H, et al.: Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 2010;59(12):3174–3180.
83. Oikarinen S, Martiskainen M, Tauriainen S, et al.: Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 2011;60(1):276–279.
84. Stene LC, Rewers M: Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies. Clinical & Experimental Immunology 2012;168(1):12–23.

85. McKinney PA, Okasha M, Parslow RC, et al.: Early social mixing and childhood Type 1 diabetes mellitus: a case-control study in Yorkshire, UK. Diabetic Medicine 2000;17(3):236–242.
86. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia 2000;43(1):47–53.
87. Kaila B, Taback SP: The effect of day care exposure on the risk of developing type 1 diabetes: ameta-analysis of case-control studies. Diabetes Care 2001;24(8):1353–1358.
88. Zinkernagel RM: Maternal antibodies, childhood infections, and autoimmune diseases. New England Journal of Medicine 2001; 345(18):1331–1335.
89. Graves PM, Barriga KJ, Norris JM, et al.: Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999;22(10):1694–1697.
90. Hummel M, Fuchtenbusch M, Schenker M, Ziegler AG: No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 2000;23(7):969–974.
91. Hyoty H, Hiltunen M, Reunanen A, et al.: Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group. Diabetologia 1993;36(12):1303– 1308.
92. Bingley PJ, Douek IF, Rogers CA, Gale EA: Influence of maternal age at delivery and birth order on risk of type 1 diabetes in childhood: prospective population based family study. Bart's-Oxford Family Study Group. BMJ 2000;321(7258):420–424.
93. Stene LC, Magnus P, Lie RT, et al.: Maternal and paternal age at delivery, birth order, and risk of childhood onset type 1 diabetes: population based cohort study. BMJ 2001;323(7309):369.
94. Stene LC, Magnus P, Lie RT, et al.: Birth weight and childhood onset type 1 diabetes: population based cohort study. BMJ 2001;322(7291):889–892.
95. Dahlquist GG, Patterson C, Soltesz G: Perinatal risk factors for childhood type 1 diabetes in Europe.The EURODIAB Substudy 2 Study Group. Diabetes Care 1999;22(10):1698–1702.
96. Kyvik KO, Bache I, Green A, et al.: No association between birth weight and Type 1 diabetes mellitus: a twin-control study. Diabetic Medicine 2000;17(2):158–162.
97. Lamb MM, Yin X, Zerbe GO, et al.: Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. Diabetologia 2009;52(10): 2064–2071.
98. Martin JM, Trink B, Daneman D, et al.: Milk proteins in the etiology of insulin-dependent diabetes mellitus (IDDM). Annals of Medicine 1991;23:447–452.
99. Gerstein HC: Cow's milk exposure and type I diabetes mellitus—a critical overview of the clinical literature. Diabetes Care 1994;17: 13–19.
100. Norris JM, Scott FW: A meta-analysis of infant diet and insulin-dependent diabetes mellitus: do biases play a role? Epidemiology 1996;7:87–92.
101. Norris JM, Beaty B, Klingensmith G, et al.: Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY). JAMA 1996;276(8):609–614.
102. Virtanen SM, Hypponen E, Laara E, et al.: Cow's milk consumption, disease-associated autoantibodies and type 1 diabetes mellitus: a follow-up study in siblings of

diabetic children. Childhood Diabetes in Finland Study Group. Diabetic Medicine 1998;15(9): 730–738.
103. Knip M, Virtanen SM, Becker D, et al.: Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). American Journal of Clinical Nutrition 2011;94(6 Suppl): 1814S–1820S.
104. Norris JM, Barriga K, Klingensmith G, et al.: Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003;290(13):1713–1720.
105. Ziegler AG, Schmid S, Huber D, et al.: Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003;290(13):1721–1728.
106. Hummel S, Pfluger M, Hummel M, et al.: Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011;34(6):1301–1305.
107. Mathieu C, Laureys J, Sobis H, et al.: 1,25-dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 1992;41:1491–1495.
108. Hypponen E, Laara E, Reunanen A, et al.: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358(9292):1500–1503.
109. Stene LC, Ulriksen J, Magnus P, Joner G: Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 2000;43(9):1093–1098.
110. Simpson M, Brady H, Yin X, et al.: No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 2011; 54(11):2779–2788.
111. Fronczak CM, Baron AE, Chase HP, et al.: In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003;26(12):3237–3242.
112. Marjamaki L, Niinisto S, Kenward MG, et al.: Maternal intake of vitamin D during pregnancy and risk of advanced beta cell autoimmunity and type 1 diabetes in offspring. Diabetologia 2010; 53(8):1599–1607.
113. Norris JM, Yin X, Lamb MM, et al.: Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007;298(12):1420–1428.
114. Miller MR, Yin X, Seifert J, et al.: Erythrocyte membrane omega-3 fatty acid levels and omega-3 fatty acid intake are not associated with conversion to type 1 diabetes in children with islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Pediatric Diabetes 2011;12(8):669–675.
115. Skyler JS: Update on worldwide efforts to prevent type 1 diabetes. Annals of the N Y Academy of Sciences 2008;1150:190–196.
116. Rewers M, Atkinson M: The possible role of enteroviruses in diabetes mellitus. In: Rotbart HA (ed.) Human Enterovirus Infections. Washington, DC: ASM, 1996, pp. 353–385.
117. Virtanen SM, Laara E, Hypponen E, et al.: Cow's milk consumption, HLA-DQB1 genotype, and type 1 diabetes: a nested case-control study of siblings of children with diabetes. Childhood Diabetes in Finland Study Group [in process citation]. Diabetes 2000;49(6):912–917.

118. Pinkey JH, Bingley PJ, Sawtell PA, et al.: Presentation and progress of childhood diabetes mellitus: a prospective population based study. The Bart's-Oxford Study Group. Diabetologia 1994; 37(1):70–74.
119. Foulis AK, Liddle CN, Farquharson MA, et al.: The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986;29(5):267–274.
120. Childhood Diabetes Research Committee–Ministry of Health and Welfare–Japan; Polish Diabetes Research Group–Poznan; The Netherlands Institute for Preventive Health Care–Leiden; Diabetes Research Center of Pittsburgh–Pennsylvania: How frequently do children die at the onset of insulin-dependent diabetes? Analyses of registry data from Japan, Poland, the Netherlands, and Allegheny County, Pennsylvania. Diabetes, Nutrition & Metabolism 1990;3:57–62.
121. Sabbah E, Savola K, Kulmala P, et al.: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes.The Childhood Diabetes in Finland Study Group. Journal of Clinical Endocrinology & Metabolism 1999;84(5):1534–1539.
122. Ortqvist E, Falorni A, Scheynius A, et al.: Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM. Acta Paediatrica 1997; 86(11):1166–1171.
123. Pipeleers D, Ling Z: Pancreatic beta cells in insulin-dependent diabetes. Diabetes/Metabolism Reviews 1992;8(3):209–227.
124. Rewers A, Chase HP, Mackenzie T, et al.: Predictors of acute complications in children with type 1 diabetes. JAMA 2002;287(19):2511–2518.
125. Secrest AM, Becker DJ, Kelsey SF, et al.: All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care 2010;33(12):2573–2579.
126. Miller RG, Secrest AM, Sharma RK, et al.: Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study cohort. Diabetes 2012; 61(11):2987–2992.
127. Orchard TJ, Secrest AM, Miller RG, Costacou T: In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53(11):2312–2319.